Pharming Group (NASDAQ:PHAR) Earns "Sell (D+)" Rating from Weiss Ratings

Key Points

• Pharming Group has received a "Sell (D+)" rating from Weiss Ratings, indicating analysts' negative outlook on its stock performance.
• Zacks Research downgraded Pharming Group from a "strong-buy" rating to a "hold," contributing to a consensus rating of "Hold" among analysts.
• Pharming Group reported $0.06 earnings per share, surpassing forecasts, with revenue of $93.20 million for the latest quarter, which was also above expectations.

Pharming Group (NASDAQ:PHAR - Get Free Report)'s stock had its "sell (d+)" rating restated by research analysts at Weiss Ratings in a research report issued on Wednesday,Weiss Ratings reports.

Separately, Zacks Research cut Pharming Group from a "strong-buy" rating to a "hold" rating in a report on Tuesday, September 30th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Pharming Group presently has a consensus rating of "Hold" and an average price target of $30.00.

Pharming Group Stock Up 0.6%

PHAR opened at $14.77 on Wednesday. The firm has a 50 day moving average price of $13.74 and a 200 day moving average price of $11.12. The company has a market cap of $1.01 billion, a PE ratio of -113.58 and a beta of 0.04. Pharming Group has a 1 year low of $7.31 and a 1 year high of $17.08. The company has a debt-to-equity ratio of 0.38, a quick ratio of 2.07 and a current ratio of 2.79.

Pharming Group (NASDAQ:PHAR - Get Free Report) last posted its earnings results on Thursday, July 31st. The company reported $0.06 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.10) by $0.16. The firm had revenue of $93.20 million during the quarter, compared to the consensus estimate of $70.36 million. Pharming Group had a negative net margin of 2.19% and a negative return on equity of 3.31%. Pharming Group has set its FY 2025 guidance at EPS. Sell-side analysts expect that Pharming Group will post -0.2 earnings per share for the current year.

Hedge Funds Weigh In On Pharming Group

A hedge fund recently bought a new stake in Pharming Group stock. EverSource Wealth Advisors LLC bought a new stake in shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Free Report) in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor bought 2,979 shares of the company's stock, valued at approximately $32,000. Institutional investors own 0.03% of the company's stock.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.